We are live on
!
Find out more
BIA
Biondo Investment Advisors Portfolio holdings
AUM
$780M
1-Year Est. Return
21.03%
This Fund
S&P 500
This Quarter
Est. Return
+4.87%
1 Year Est. Return
+21.03%
3 Year Est. Return
+89.14%
5 Year Est. Return
+116.93%
10 Year Est. Return
+716.37%
AUM
$422M
AUM Growth
+$23.2M
(+5.8%)
Cap. Flow
+$12.1M
Cap. Flow
% of AUM
2.88%
Top 10 Holdings %
Top 10 Hldgs %
50.61%
Holding
90
New
9
Increased
55
Reduced
20
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$6.31M |
| 2 |
Atlassian
TEAM
|
+$3.94M |
| 3 |
SIVB
SVB Financial Group
SIVB
|
+$3.18M |
| 4 |
Truist Financial
TFC
|
+$2.76M |
| 5 |
Alibaba
BABA
|
+$1.68M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$7.88M |
| 2 |
Mastercard
MA
|
+$1.81M |
| 3 |
DuPont de Nemours
DD
|
+$932K |
| 4 |
Apple
AAPL
|
+$791K |
| 5 |
Idexx Laboratories
IDXX
|
+$596K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37% |
| 2 | Technology | 17.07% |
| 3 | Financials | 13.73% |
| 4 | Consumer Discretionary | 8.79% |
| 5 | Communication Services | 5.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Mastercard
MA
$470B
| $37.7M | 8.93% |
142,433
-7,242
| -5% | -$1.81M |
|
2
Intuitive Surgical
ISRG
$120B
| $35.8M | 8.48% |
204,486
+825
| +0.4% | +$141K |
|
|
3
Apple
AAPL
$4.78T
| $24.3M | 5.77% |
491,972
-16,240
| -3% | -$791K |
|
|
EXAS
4
DELISTED
Exact Sciences
EXAS
| $24.1M | 5.7% |
203,820
+7,200
| +4% | +$725K |
|
5
Illumina
ILMN
$29.6B
| $21.3M | 5.05% |
59,460
+2,737
| +5% | +$864K |
|
|
ABMD
6
DELISTED
Abiomed Inc
ABMD
| $16.3M | 3.86% |
62,539
-1,376
| -2% | -$365K |
|
|
7
Idexx Laboratories
IDXX
$42.5B
| $15.9M | 3.76% |
57,621
-2,420
| -4% | -$596K |
|
8
Alphabet (Google) Class A
GOOGL
$3.92T
| $14.5M | 3.45% |
268,680
+5,680
| +2% | +$329K |
|
|
XYZ
9
Block Inc
XYZ
$45.6B
| $13.4M | 3.17% |
184,405
-1,985
| -1% | -$139K |
|
10
Vertex Pharmaceuticals
VRTX
$121B
| $10.2M | 2.43% |
55,850
+900
| +2% | +$157K |
|
11
JPMorgan Chase
JPM
$927B
| $9.96M | 2.36% |
89,073
-1,615
| -2% | -$178K |
|
12
Adobe
ADBE
$86.8B
| $9.22M | 2.19% |
31,285
+437
| +1% | +$121K |
|
13
VF Corp
VFC
$6.56B
| $8.7M | 2.06% |
99,585
-5,776
| -5% | -$498K |
|
14
Microsoft
MSFT
$2.86T
| $7.16M | 1.7% |
53,303
+55
| +0.1% | +$6.98K |
|
15
Procter & Gamble
PG
$340B
| $7.15M | 1.7% |
65,215
+272
| +0.4% | +$29K |
|
|
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $6.9M | 1.64% |
+73,090
| New | +$6.31M |
|
17
Lockheed Martin
LMT
$132B
| $6.67M | 1.58% |
18,224
-300
| -2% | -$100K |
|
18
McDonald's
MCD
$188B
| $6.23M | 1.48% |
29,821
+170
| +0.6% | +$33.7K |
|
19
Lowe's Companies
LOW
$114B
| $5.97M | 1.42% |
59,195
+215
| +0.4% | +$22.7K |
|
20
Align Technology
ALGN
$12.2B
| $5.96M | 1.41% |
21,793
+2,888
| +15% | +$872K |
|
21
Chevron
CVX
$389B
| $5.8M | 1.38% |
46,193
+29
| +0.1% | +$3.51K |
|
|
SIVB
22
DELISTED
SVB Financial Group
SIVB
| $5.33M | 1.26% |
23,750
+13,755
| +138% | +$3.18M |
|
23
Verizon
VZ
$188B
| $5.25M | 1.25% |
91,921
+905
| +1% | +$52.1K |
|
24
Johnson & Johnson
JNJ
$631B
| $5.23M | 1.24% |
37,323
-188
| -0.5% | -$26K |
|
25
Intel
INTC
$492B
| $5.21M | 1.24% |
108,204
+170
| +0.2% | +$8.43K |
|
Similar funds
LA
UBV
SG
RTM
TCMX
QCMNJ
TIS
MO
Biondo Investment Advisors's Q2 2019 Portfolio in Review
As of Q2 2019, Biondo Investment Advisors held 90 positions worth $422M, up 5.8% from $399M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Biondo Investment Advisors's Q2 2019 filing shows 9 new, 55 increased, 20 reduced and 2 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 73,090 shares worth $6.9M. The largest sale was Regeneron Pharmaceuticals, an estimated $7.88M.
By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 38% a quarter earlier, followed by Technology and Financials.
- Biondo Investment Advisors's largest Q2 2019 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 73,090 shares worth $6.9M.
- Biondo Investment Advisors added most to Atlassian in Q2 2019, an estimated $3.94M increase.
- Biondo Investment Advisors's biggest Q2 2019 reduction was Regeneron Pharmaceuticals, cutting an estimated $7.88M.
- Biondo Investment Advisors fully exited PrimeEnergy Resources in Q2 2019, selling an estimated $285K.
- Biondo Investment Advisors's ten largest holdings make up 51% of its $422M portfolio in Q2 2019.
- Biondo Investment Advisors opened 9 new positions and closed 2 in Q2 2019.
- Biondo Investment Advisors's portfolio value rose 5.8% quarter-over-quarter to $422M.
Based on Biondo Investment Advisors's 13F filing for Q2 2019, filed 6 Aug 2019.